Supplementary Material

Elaborated Methods

Patients with schizophrenia and bipolar disorder

Diagnoses were confirmed by clinical interview by a psychiatrist using the Diagnostic

Interview for Genetic Studies (DIGS III) 1. Numbers of patients receiving antipsychotics alone or in combination are described in Supplementary Table 1. Patients with a concurrent Axis I diagnosis, a history of alcohol or drug abuse/dependence, head injuries with loss of consciousness, seizures, central nervous system infection, untreated diabetes or hypertension, current or past cardiac or neurological disease, significant cerebral anatomic abnormality, contraindications to MRI or mental retardation were excluded.

Healthy control group

Exclusion criteria consisted of a personal history of or a first-degree relative with a DSM-IV

Axis I psychiatric diagnosis, a history of alcohol or drug abuse/dependence, head injuries with loss of consciousness, seizures, central nervous system infection, untreated diabetes or hypertension, current or past cardiac or neurological disease, significant cerebral anatomic abnormality, contraindications to

MRI or mental retardation.

Symptoms and cognitive measures

Symptom severity in patients was evaluated with the Positive and Negative Syndrome Scale

(PANSS) 2. Positive, negative, general and total symptom scores were calculated. For BD patients, manic symptoms were assessed with the Young Mania Rating Scale (YMRS) 3 and depressive symptoms with the Montgomery-Åsberg Depression Rating Scale (MADRS) 4. Additionally, history of psychotic features in individuals with BD was defined as experiencing at least one manic or depressive episode with delusions or hallucinations (DSM-IV). The National Adult Reading Test

(NART) was administered to assess (premorbid) intellectual functioning in patients.

Whole brain tractography

To define the 3D space within which the fibers are tracked, we used T1 images to build a tractography propagation mask for each subject 5-7, followed by linear registration of the mask on

DWI data. The registration between T1-weighted and DW data and the quality of the propagation mask were checked visually. This mask includes whole brain tissue as opposed to the more standardised method of only including regions with high FA. The standard method aims to detect WM using an arbitrary threshold FA map, yet in practice some WM regions fail to be detected due to partial volume effects from limited resolution or inadequate detection at crossing fibers.

Whole brain regularized streamline deterministic tractography (one seed per voxel, step forward = 0.5 mm, bilateral propagation) was performed in each subject’s native space 8. This allows

WM tracts to be reconstructed using a step-by-step approach following multidirectional diffusion orientation 9. This process was interrupted in the case of excessive tract length (> 85mm because short

U-shaped fibers do not exceed this size), tract propagation outside the mask or excessive angle between two steps (> 30°). The mask was used for seeding and to define the space where fibers were tracked.

Tractogram segmentation

To segment the whole brain into SWM tracts, we used the atlas recently built based on 79 healthy subjects by Guevara et al. 10, composed of 100 bundles, 35 of which are common in both hemispheres. Authors selected only the short fibers between 20-80mm and used an ROI image to label each bundle according to the two regions it connects (See Table 2 for abbreviations for all anatomical regions). Moreover, to test reproducibility of the atlas, the same processing pipeline was applied to a different group of subjects from a validation database. Finally, bundles included in the final atlas were those which were successfully segmented with low variability in shape and number of fibers among subjects. We extracted the mean gFA along each reconstructed SWM bundle as an estimation of its integrity 11 as it is the most widely studied DWI variable in SZ and BD. Only the most stable bundles (bundles which were present in 100% of the subjects), were selected for statistical analyses in the present study. Supplementary References

1. Nurnberger JI, Jr., Blehar MC, Kaufmann CA, et al. Diagnostic interview for genetic studies. Rationale, unique features, and training. NIMH Genetics Initiative. Archives of general psychiatry Nov 1994;51(11):849-859; discussion 863-844. 2. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987;13(2):261-276. 3. Young RC, Biggs JT, Ziegler VE, Meyer DA. A Rating Scale for Mania: Reliability, Validity and Sensitivity. British Journal of Psychiatry 2018;133(5):429-435. 4. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. The British journal of psychiatry : the journal of mental science Apr 1979;134:382-389. 5. Guevara P, Poupon C, Riviere D, Cointepas Y, Descoteaux M, Thirion B, Mangin JF. Robust clustering of massive tractography datasets. NeuroImage Feb 1 2011;54(3):1975-1993. 6. Guevara P, Duclap D, Poupon C, et al. Automatic fiber bundle segmentation in massive tractography datasets using a multi-subject bundle atlas. NeuroImage Jul 16 2012;61(4):1083- 1099. 7. Guevara P, Duclap D, Marrakchi-Kacem L, Rivière D, Cointepas Y, Poupon C, Mangin J-F. Accurate tractography propagation mask using T1-weighted data rather than FA. Vol 19; 2011. 8. Perrin M, Cointepas Y, Cachia A, et al. Connectivity-based parcellation of the cortical mantle using q-ball diffusion imaging. International journal of biomedical imaging 2008;2008:368406. 9. Descoteaux M, Angelino E, Fitzgibbons S, Deriche R. Regularized, fast, and robust analytical Q-ball imaging. Magnetic resonance in medicine Sep 2007;58(3):497-510. 10. Guevara M, Roman C, Houenou J, Duclap D, Poupon C, Mangin JF, Guevara P. Reproducibility of superficial white matter tracts using diffusion-weighted imaging tractography. NeuroImage Feb 15 2017;147:703-725. 11. Beaulieu C. Chapter 8 - The Biological Basis of Diffusion Anisotropy. Diffusion MRI (Second Edition). San Diego: Academic Press; 2014:155-183.

Supplementary Table 1. Breakdown of antipsychotic medications

Schizophrenia Antipsychotic (n) Bipolar (n) amisulpride - 1 aripiprazole 2 - chlorpromazine - 2 clozapine 2 - cyamemazine - 3 haloperidol 1 - levomepromazine 1 - loxapine - 1 olanzapine 1 1 quetiapine 1 - risperidone 7 - aripriprazole/paliperidone 1 - aripriprazole/chlorpromazine - 1 aripriprazole/clozapine 1 - aripriprazole/clozapine/cyamemazine 1 - aripriprazole/cyamemazine 3 1 aripriprazole/cyamemazine/risperidone 1 - clozapine/cyamemazine 1 - clozapine/cyamemazine/risperidone 1 - clozapine/haloperidol 1 - clozapine/loxapine 1 - clozapine/olanzapine 1 - cyamemazine/olanzapine 1 - cyamemazine/risperidone - 1 loxapine/risperidone 2 1 olanzapine/levomepromazine - 2 risperidone/cyamemazine 1 -

Supplementary Table 2. Post hoc SWM mean gFA differences

Controls vs SZ Controls vs BD SZ vs BD p Value p Value p Value p Bundle H F (df) p Value for FDR F (df) for FDR F (df) p Value for FDR Value Adjusted Adjusted Adjusted

CAC - PrCu L 11.4 (3, 81) <0.001 <0.001a 4.5 (3, 82) 0.006 0.01a 5.1 (3, 59) 0.003 0.009b CMF - L 3.5 (3, 81) 0.02 0.02a 3.4 (3, 82) 0.02 0.03a 2.0 (3, 59) 0.1 0.13 PrC_2

IP - MT L 4.4 (3, 81) 0.006 0.009 5.3 (3, 82) 0.002 0.009a 5.8 (3, 59) 0.002 0.009

MOF - ST L 4.5 (3, 81) 0.007 0.009a 1.7 (3, 82) 0.20 0.16 4.7 (3, 59) 0.005 0.01b

Op - Ins L 5.0 (3, 81) 0.003 0.01a 2.8 (3, 82) 0.04 0.05a 2.2 (3, 59) 0.1 0.10

Op - PrC L 4.8 (3, 81) 0.004 0.01a 4.4 (3, 82) 0.007 0.01a 5.3 (3, 59) 0.003 0.009

PoC - Ins L 8.3 (3, 81) <0.001 0.01a 4.1 (3, 82) 0.009 0.02a 0.4 (3, 59) 0.74 0.70

PoCi - PrCu L 7.1 (3, 81) <0.001 0.01 3.5 (3, 82) 0.02 0.03a 3.8 (3, 59) 0.01 0.02

PoC - SM_2 L 5.0 (3, 81) 0.003 0.01 5.1 (3, 82) 0.003 0.009 4.3 (3, 59) 0.008 0.01 CMF - R 3.3 (3, 81) 0.02 0.02a 3.2 (3, 82) 0.03 0.03a 5.9 (3, 59) 0.001 0.009b PrC_2

IP - MT R 6.5 (3, 81) 0.001 0.02a 10.1 (3, 82) <0.001 <0.001a 5.1 (3, 59) 0.003 0.009

LOF - RMF R 3.2 (3, 81) 0.03 0.02a 3.5 (3, 82) 0.02 0.03 4.8 (3, 59) 0.005 0.01b

MOF - ST R 2.5 (3, 81) 0.06 0.02 4.8 (3, 82) 0.004 0.01a 2.4 (3, 59) 0.07 0.10

Op - PrC R 4.2 (3, 81) 0.008 0.02a 5.4 (3, 82) 0.002 0.009 9.1 (3, 59) <0.001 <0.001b PoC - R 3.8 (3, 81) 0.01 0.02a 5.5 (3, 82) 0.002 0.009a 4.4 (3, 59) 0.007 0.01b PrC_3

PoC - SM R 7.0 (3, 81) <0.001 0.02a 3.0 (3, 82) 0.04 0.04a 2.3 (3, 59) 0.08 0.10

RMF - SF R 7.0 (3, 81) <0.001 0.02a 5.2 (3, 82) 0.003 0.009a 4.3 (3, 59) 0.008 0.01b Between-group post hoc analyses of 17 SWM bundles that were significant (p ≤ 0.05, FDR adjusted) following ANCOVA among the three study groups, with age and sex as covariates.

Abbreviation: FDR, false discovery rate; BD, bipolar disorder; SZ, schizophrenia; L, left; R, right. a Significantly greater mean gFA in healthy controls. b Significantly greater mean gFA in people with BD as compared to people with SZ.

Supplementary Table 3: Comparison of gFA Between BD Patients With at Least 1 PF Episode vs No PF History p Value for FDR Bundle H F (df) p Value Adjusted CAC - PrCu L 0.9 (3,28) 0.45 0.50 CMF - PrC_2 L 1.1 (3,28) 0.37 0.50 IP - MT L 3.4 (3,28) 0.03 0.09 Op - Ins L 1.3 (3,28) 0.29 0.42 Op - PrC L 2.3 (3,28) 0.10 0.18 PoC - Ins L 0.9 (3,28) 0.43 0.50 PoCi - PrCu L 0.9 (3,28) 0.47 0.50 PoC - SM_2 L 4.4 (3,28) 0.01 0.09 CMF - PrC_2 R 2.4 (3,28) 0.09 0.18 IP - MT R 3.3 (3,28) 0.03 0.09 LOF - RMF R 3.7 (3,28) 0.02 0.09 MOF - ST R 2.4 (3,28) 0.09 0.18 Op - PrC R 5.4 (3,28) 0.005 0.08 PoC - PrC_3 R 3.7 (3,28) 0.02 0.09 PoC - SM R 0.6 (3,28) 0.64 0.64 RMF - SF R 1.7 (3,28) 0.20 0.32 Abbreviation: FDR, false discovery rate; BD, bipolar disorder; H, hemisphere; L, left; R, right; PF, psychotic feature.

Supplementary Table 4. Correlations Between gFA of Bundles and Illness Duration in Patients with Schizophrenia and Bipolar Disorder

Schizophrenia Bipolar Bundle H n r P Value n r p-value P Value for FDR Adjusted CAC - PrCu L 31 0.18 0.33 32 -0.11 0.56 0.82 CMF - PrC L 31 -0.16 0.41 32 -0.37 0.05 0.27 CMF - PrC_2 L 31 0.11 0.58 32 -0.40 0.03 0.20 CMF - RMF L 31 0.08 0.67 32 -0.19 0.31 0.74 CMF - SF L 31 0.11 0.56 32 -0.43 0.02 0.20 IC - PrCu L 31 0.05 0.81 32 0.12 0.54 0.82 IP - LOF L 31 0.03 0.87 32 -0.19 0.32 0.74 IP - MT L 31 0.10 0.59 32 -0.16 0.41 0.82 IP - SP L 31 0.30 0.11 32 -0.07 0.73 0.91 IT - MT L 31 0.14 0.46 32 -0.01 0.94 0.98 LOF - Or L 31 -0.01 0.97 32 -0.25 0.19 0.62 LOF - RMF L 31 -0.08 0.66 32 -0.20 0.30 0.74 LOF - L 31 -0.24 0.20 32 0.08 0.68 0.87 LOFRMF_2 - ST L 31 -0.04 0.83 32 -0.40 0.03 0.20 MOF - ST L 31 -0.06 0.75 32 -0.30 0.11 0.42 Op - Ins L 31 0.07 0.71 32 -0.14 0.46 0.82 Op - PrC L 31 0.29 0.12 32 -0.35 0.06 0.30 Op - SF L 31 -0.15 0.44 32 -0.41 0.02 0.20 Or - Ins L 31 -0.01 0.96 32 -0.11 0.57 0.82 PoC - Ins L 31 -0.07 0.71 32 0.13 0.50 0.82 PoCi - PrCu L 31 0.15 0.42 32 -0.03 0.88 0.98 PoCi - RAC L 31 -0.38 0.04 32 0.02 0.93 0.98 PoCi - SF L 31 0.29 0.12 32 -0.13 0.50 0.82 PoC - PrC L 31 -0.03 0.89 32 -0.28 0.13 0.47 PoC - PrC_2 L 31 0.02 0.90 32 -0.10 0.59 0.82 PoC - PrC_3 L 31 0.05 0.79 32 -0.40 0.03 0.20 PoC - PrC_4 L 31 0.11 0.56 32 -0.20 0.29 0.74 PoC - SM L 31 0.19 0.32 32 0.06 0.77 0.91 PoC - SM_2 L 31 -0.03 0.86 32 -0.31 0.10 0.42 PrC - Ins L 31 -0.1 0.61 32 0.004 0.98 0.98 RMF - SF L 31 0.01 0.98 32 -0.11 0.58 0.82 SP - SM L 31 0.003 0.99 32 0.49 0.01 0.16 ST - TR L 31 -0.01 0.97 32 -0.16 0.40 0.82 Pr - Ins L 31 0.01 0.96 32 -0.02 0.90 0.98 CAC - PrCu R 31 0.15 0.44 32 -0.15 0.44 0.82 CMF - PrC R 31 0.06 0.76 32 0.05 0.77 0.91 CMF - PrC_2 R 31 -0.12 0.54 32 -0.09 0.64 0.87 CMF - SF R 31 0.28 0.14 32 -0.14 0.45 0.82 CMF - SF_2 R 31 0.24 0.21 32 0.08 0.67 0.87 IC - PrCu R 31 0.03 0.90 32 0.25 0.18 0.62 IP - IT R 31 0.08 0.69 32 -0.22 0.24 0.71 IP - MT R 31 0.18 0.35 32 0.01 0.95 0.98 IP - SP R 31 0.17 0.36 32 -0.30 0.11 0.42 IT - MT R 31 -0.04 0.83 32 0.06 0.75 0.91 LOF - MOF R 31 0.15 0.43 32 -0.14 0.45 0.82 LOF - RMF R 31 -0.18 0.33 32 0.12 0.53 0.82 LOF - ST R 31 -0.15 0.43 32 -0.11 0.56 0.82 MOF - ST R 31 -0.07 0.73 32 -0.31 0.09 0.42 MT - ST R 31 -0.26 0.17 32 -0.11 0.56 0.82 Op - Ins R 31 -0.13 0.49 32 -0.13 0.51 0.82 Op - PrC R 31 -0.11 0.55 32 -0.40 0.03 0.2 Or - Ins R 31 -0.16 0.40 32 -0.02 0.93 0.98 PoCi - PrCu R 31 0.002 0.99 32 -0.18 0.35 0.78 PoCi - RAC R 31 0.05 0.78 32 -0.20 0.30 0.74 PoC - PrC R 31 0.24 0.21 32 -0.20 0.28 0.74 PoC - PrC_2 R 31 0.17 0.37 32 -0.24 0.20 0.62 PoC - PrC_3 R 31 0.26 0.16 32 -0.45 0.01 0.16 PoC - SM R 31 0.01 0.94 32 -0.04 0.85 0.97 PoC - SP R 31 0.10 0.61 32 0.01 0.98 0.98 PrC - Ins R 31 -0.16 0.41 32 0.08 0.66 0.87 RAC - SF R 31 0.05 0.79 32 -0.48 0.01 0.16 RMF - SF R 31 0.18 0.34 32 0.04 0.84 0.97 SP - SM R 31 0.05 0.77 32 -0.44 0.01 0.16 ST - TT R 31 -0.05 0.78 32 -0.38 0.04 0.24 Tr - Ins R 31 -0.18 0.33 32 -0.13 0.49 0.82

Supplementary Table 5: Pearson Correlations Between SWM gFA and Mean Daily Olanzapine Equivalent Dose in Patients

p Value Bundle H n r p Value for FDR Adjusted CAC - PrCu L 42 -0.34 0.03 0.20 CMF - PrC L 42 -0.14 0.38 0.61 CMF - PrC_2 L 42 -0.11 0.50 0.67 CMF - RMF L 42 -0.02 0.92 0.95 CMF - SF L 42 0.06 0.70 0.84 IC - PrCu L 42 -0.47 <0.001 0.04 IP - LOF L 42 -0.21 0.19 0.47 IP - MT L 42 -0.22 0.15 0.47 IP - SP L 42 -0.29 0.06 0.30 IT - MT L 42 -0.44 <0.001 0.05 LOF - Or L 42 0.01 0.93 0.95 LOF - RMF L 42 0.04 0.82 0.89 LOF - RMF_2 L 42 -0.13 0.42 0.62 LOF - ST L 42 -0.38 0.01 0.10 MOF - ST L 42 -0.41 0.01 0.08 Op - Ins L 42 -0.16 0.30 0.52 Op - PrC L 42 -0.21 0.18 0.47 Op - SF L 42 -0.08 0.60 0.77 Or - Ins L 42 -0.13 0.41 0.62 PoC - Ins L 42 -0.16 0.32 0.55 PoCi - PrCu L 42 -0.02 0.90 0.94 PoCi - RAC L 42 -0.25 0.12 0.42 PoCi - SF L 42 -0.49 <0.001 0.03 PoC - PrC L 42 -0.18 0.26 0.49 PoC - PrC_2 L 42 0.01 0.97 0.97 PoC - PrC_3 L 42 -0.15 0.35 0.58 PoC - PrC_4 L 42 -0.22 0.17 0.47 PoC - SM L 42 -0.02 0.89 0.94 PoC - SM_2 L 42 -0.25 0.11 0.42 PrC - Ins L 42 -0.18 0.24 0.48 RMF - SF L 42 0.13 0.40 0.62 SP - SM L 42 -0.12 0.46 0.65 ST - TR L 42 -0.28 0.07 0.32 Pr - Ins L 42 0.21 0.19 0.47 CAC - PrCu R 42 -0.24 0.13 0.45 CMF - PrC R 42 -0.04 0.82 0.89 CMF - PrC_2 R 42 -0.07 0.68 0.83 CMF - SF R 42 -0.04 0.79 0.88 CMF - SF_2 R 42 -0.11 0.48 0.66 IC - PrCu R 42 -0.54 <0.001 0.01 IP - IT R 42 -0.14 0.38 0.61 IP - MT R 42 0.18 0.25 0.48 IP - SP R 42 -0.12 0.45 0.65 IT - MT R 42 -0.20 0.19 0.47 LOF - MOF R 42 -0.06 0.71 0.84 LOF - RMF R 42 -0.17 0.29 0.51 LOF - ST R 42 -0.09 0.58 0.76 MOF - ST R 42 -0.19 0.22 0.47 MT - ST R 42 -0.19 0.23 0.48 Op - Ins R 42 0.11 0.49 0.67 Op - PrC R 42 -0.20 0.21 0.47 Or - Ins R 42 -0.05 0.75 0.85 PoCi - PrCu R 42 -0.45 <0.001 0.04 PoCi - RAC R 42 -0.34 0.03 0.20 PoC - PrC R 42 -0.18 0.25 0.48 PoC - PrC_2 R 42 -0.28 0.07 0.32 PoC - PrC_3 R 42 -0.20 0.20 0.47 PoC - SM R 42 -0.20 0.20 0.47 PoC - SP R 42 -0.21 0.18 0.47 PrC - Ins R 42 -0.27 0.09 0.35 RAC - SF R 42 -0.31 0.05 0.27 RMF - SF R 42 -0.07 0.66 0.83 SP - SM R 42 -0.31 0.04 0.26 ST - TT R 42 -0.33 0.03 0.23 Tr - Ins R 42 -0.05 0.74 0.85 Abbreviation: FDR, false discovery rate; H; hemisphere; L, left; R, right.

Bold p values indicate significant results after FDR correction.

Supplementary Table 6. Correlations between SWM gFA and Symptom Severity as assessed by the PANSS in Patients

a) People with schizophrenia

Positive Negative General Total p Value p Value Bundle H n r p Value r p Value for FDR r p Value for FDR r p Value Adjusted Adjusted CAC - PrCu L 31 0.13 0.48 0.38 0.03 0.16 0.00 0.99 0.99 0.22 0.24 CMF - L 31 -0.09 0.64 0.20 0.27 0.26 0.16 0.51 0.18 0.33 PrC_2 0.56 IP - MT L 31 -0.14 0.46 0.13 0.48 0.64 0.02 0.93 0.99 0.01 0.95 MOF - ST L 31 -0.19 0.30 0.18 0.35 0.56 -0.31 0.09 0.36 -0.15 0.41 Op - Ins L 31 -0.20 0.29 -0.15 0.41 0.60 -0.12 0.53 0.99 -0.20 0.27 Op - PrC L 31 -0.03 0.89 0.19 0.30 0.56 0.32 0.08 0.36 0.23 0.20 PoC - Ins L 31 -0.07 0.69 0.10 0.58 0.67 -0.22 0.23 0.61 -0.10 0.60 PoCi - PrCu L 31 -0.18 0.32 0.38 0.04 0.16 0.01 0.96 0.99 0.10 0.60 PoC - SM_2 L 31 -0.02 0.90 0.54 0.002 0.03 0.07 0.71 0.99 0.26 0.16 CMF - R 31 -0.08 0.67 0.36 0.04 0.36 0.05 0.36 0.31 0.09 PrC_2 0.16 IP - MT R 31 0.05 0.80 0.10 0.59 0.67 0.03 0.89 0.99 0.08 0.69 LOF - RMF R 31 -0.11 0.54 -0.01 0.95 0.95 0.02 0.90 0.99 -0.04 0.84 Op - PrC R 31 -0.13 0.50 0.25 0.17 0.45 0.32 0.08 0.36 0.22 0.24 PoC - PrC_3 R 31 -0.21 0.25 0.31 0.09 0.29 -0.09 0.64 0.99 0.01 0.97 PoC - SM R 31 0.12 0.53 0.03 0.89 0.95 0.18 0.35 0.80 0.15 0.44 RMF - SF R 31 -0.26 0.15 0.18 0.32 0.56 -0.05 0.79 0.99 -0.05 0.80

b) People with bipolar disorder

Positive Negative General Total p p p p Bundle H n r Value n r Value n r Value n r Value CAC - PrCu L 30 -0.09 0.65 30 -0.10 0.61 28 -0.25 0.19 28 -0.21 0.29 CMF - -0.26 0.16 28 -0.13 0.50 28 -0.07 0.71 PrC_2 L 30 0.16 0.39 30 IP - MT L 30 0.29 0.12 30 0.06 0.77 28 0.15 0.44 28 0.20 0.31 Op - Ins L 30 -0.24 0.20 30 0.06 0.75 28 -0.10 0.61 28 -0.13 0.50 Op - PrC L 30 0.22 0.23 30 0.06 0.77 28 0.23 0.25 28 0.24 0.21 PoC - Ins L 30 -0.27 0.15 30 -0.03 0.87 28 -0.22 0.27 28 -0.23 0.24 PoCi - PrCu L 30 0.16 0.40 30 -0.15 0.43 28 -0.06 0.76 28 -0.01 0.95 PoC - SM_2 L 30 0.02 0.91 30 -0.22 0.24 28 -0.20 0.30 28 -0.16 0.41 CMF - -0.03 0.87 28 -0.15 0.46 28 -0.12 0.53 PrC_2 R 30 -0.09 0.62 30 IP - MT R 30 -0.11 0.56 30 0.00 0.98 28 -0.12 0.53 28 -0.10 0.61 LOF - RMF R 30 0.05 0.79 30 -0.09 0.62 28 -0.11 0.58 28 -0.08 0.69 MOF - ST R 30 -0.05 0.78 30 -0.33 0.08 28 -0.33 0.09 28 -0.27 0.16 Op - PrC R 30 0.32 0.09 30 -0.28 0.14 28 -0.14 0.47 28 -0.02 0.92 PoC - PrC_3 R 30 0.26 0.16 30 0.05 0.80 28 0.08 0.70 28 0.15 0.44 PoC - SM R 30 0.07 0.69 30 0.25 0.18 28 0.29 0.14 28 0.29 0.13 RMF - SF R 30 -0.08 0.67 30 -0.10 0.58 28 -0.19 0.33 28 -0.17 0.40